文献速递临床试验与 GCP流行病学与生物统计

罕见病概念验证药物试验招募挑战:三叉神经痛研究经验

Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience.
PubMed 文献 · Trials · 2018-12-27

本研究描述了一项在三叉神经痛患者中开展的vixotrigine IIa期研究遇到的招募挑战。该研究为国际多中心、安慰剂对照、随机撤药设计,计划入组30例,因招募困难将中心从5个扩展至25个。核心中心预筛636例中仅8.1%入组、1.9%完成研究,不合格原因包括诊断变更、年龄>80岁、语言/距离/行动问题等。

要点

  • 三叉神经痛药物试验招募困难,核心中心预筛合格者中仅8.1%入组、1.9%完成研究。
  • 预筛不合格常见原因:诊断变更24.8%、年龄>80岁23.9%、语言/距离/行动19.4%。
  • 未来研究设计应针对诊断变更、治疗变更焦虑及距离语言行动问题优化招募策略。

核心结论

  • 本研究中招募挑战的因素包括诊断变更、对治疗变更的焦虑以及距离、语言和行动问题。
  • 未来研究应尽可能设计以应对这些招募挑战。

研究设计与样本

  • 国际多中心、安慰剂对照、随机撤药研究,包括7天导入期、21天开放标签期和28天双盲期。
  • 计划入组30例三叉神经痛患者,随机分配至vixotrigine或安慰剂。
  • 招募前需停用所有抗癫痫药物,加巴喷丁或普瑞巴林除外;试验后患者恢复原用药。
  • 招募中心从原计划5个核心中心扩展至共25个招募中心。

主要发现

  • 核心中心预筛636例中322例(50.6%)被认为合格,其中56/322(17.4%)接受筛选。
  • 合格者中26/322(8.1%)入组研究,6/322(1.9%)完成研究。
  • 所有中心共筛选125例,67/125(53.6%)入组。
  • 预筛不合格原因:诊断变更78/314(24.8%)、年龄>80岁75/314(23.9%)、语言/距离/行动61/314(19.4%)、非心脏医学问题53/314(16.9%)。
  • 筛选期常见不合格原因包括心电图失败、疼痛不足和诊断变更。

临床怎么用

  • 开展三叉神经痛药物试验前应充分评估诊断变更风险并制定应对措施。
  • 招募策略需考虑年龄>80岁、语言/距离/行动障碍及非心脏合并症对合格性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to describe recruitment challenges encountered during a phase IIa study of vixotrigine, a state and use-dependent Nav1.7 channel blocker, in individuals with trigeminal neuralgia. METHODS: This was an international, multicenter, placebo-controlled, randomized withdrawal study that included a 7-day run-in period, a 21-day open-label phase, and a 28-day double-blind phase in which patients (planned n = 30) were randomized to vixotrigine or placebo. Before recruitment, all antiepileptic drugs had to be stopped, except for gabapentin or pregabalin. After the trial, patients returned to their original medications. Patient recruitment was expanded beyond the original five planned (core) centers in order to meet target enrollment (total recruiting sites N = 25). Core sites contributed data related to patient identification for study participation (prescreening data). Data related to screening failures and study withdrawal were also analyzed using descriptive statistics. RESULTS: Approximately half (322/636; 50.6%) of the patients who were prescreened at core sites were considered eligible for the study and 56/322 (17.4%) were screened. Of those considered eligible, 26/322 (8.1%) enrolled in the study and 6/322 (1.9%) completed the study. In total, 125 patients were screened across all study sites and 67/125 (53.6%) were enrolled. At prescreening, reasons for noneligibility varied by site and were most commonly diagnosis change (78/314; 24.8%), age > 80 years (75/314; 23.9%), language/distance/mobility (61/314; 19.4%), and noncardiac medical problems (53/314; 16.9%). At screening, frequently cited reasons for noneligibility included failure based on electrocardiogram, insufficient pain, and diagnosis change. CONCLUSIONS: Factors contributing to recruitment challenges encountered in this study included diagnosis changes, anxiety over treatment changes, and issues relating to distance, language, and mobility. Wherever possible, future studies should be designed to address these challenges. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01540630 . EudraCT, 2010-023963-16. 07 Aug 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zakrzewska JM, Palmer J, Bendtsen L, et al. Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience. Trials. 2018. PMID: 30587219. doi:10.1186/s13063-018-3045-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。